Not investment advice. See /legal#editorial

ASCO 2026 preview · Chicago · May 29 – June 2

Pre-ASCO 2026: Chinese-origin assets in the Plenary Session; 298 Chinese-attributed abstracts across the program; updated assessment of the 2024–2025 out-licensing cohort.

The Plenary Session of ASCO 2026 includes Late-Breaking Abstract 4 (LBA4), a randomized comparison of ivonescimab (a PD-1/VEGF bispecific antibody developed by Akeso and licensed ex-China to Summit Therapeutics) against tislelizumab (a PD-1 monoclonal antibody from BeOne Medicines, formerly BeiGene), each combined with platinum-doublet chemotherapy, in first-line non-small cell lung cancer (NSCLC). Both arms originate in China. Of the meeting’s 7,295 abstracts, 298 (4.1%) are attributable to a Chinese-origin sponsor or asset by combined title and body match. The program contains three additional Late-Breaking Abstracts on Chinese-origin assets outside the Plenary Session. Five topics organize the remainder of this issue.

• Akeso /
  Summit Plenary readout (LBA4) — HARMONi-6. Ivonescimab + chemotherapy vs tislelizumab + chemotherapy in previously untreated advanced squamous NSCLC. Overall survival readout. Enrolled at Chinese clinical sites; does not directly add to the U.S. FDA dossier.
  Ivonescimab U.S. status — three concurrent tracks
  A

  Near-term, narrow. Global HARMONi trial in EGFR-mutated non-squamous NSCLC post-EGFR-TKI. BLA accepted; PDUFA November 14, 2026 — first U.S. action date for the asset, inside this report’s forward calendar window.

  B

  Broad, franchise-defining. HARMONi-3 vs pembrolizumab + chemotherapy in 1L NSCLC (global). April 30, 2026 squamous-cohort interim PFS missed the early-significance bar (iDMC continuation; Summit shares ~−26%). Squamous final PFS 2H 2026; non-squamous final 1H 2027.

  C

  Supportive / China. HARMONi-2 (mono vs pembro, positive) and HARMONi-6 (combo vs tisle, squamous, China).
  Cross-read. Post-April-30, LBA4 functions as a cross-read on the HARMONi-3 squamous interim: same drug, same histology, different comparator (tisle vs pembro), different geography (China-only vs global).

  • Strong OS reading — favors comparator-strength as the explanation; keeps the broad 1L thesis intact.
  • Weak OS reading — tilts toward a geographic / population-effect explanation (cf. the Asian-subset PFS differential in the HARMONi EGFR data); compounds the April 30 setback.
• BeOne Tislelizumab supporting data outside the plenary. Two Rapid Oral sessions: (i) biomarker-stratified perioperative tislelizumab + chemotherapy vs chemotherapy in locally advanced gastric / gastroesophageal junction adenocarcinoma (GC/GEJC), randomized Phase 2 enrolling both tsMHC-II-positive and tsMHC-II-negative cohorts (abstract 2513); and (ii) the KCSG-sponsored SPECTRUM trial (LY22-07; Korean Cancer Study Group), using BeOne's tislelizumab + pemetrexed in relapsed/refractory primary diffuse large B-cell lymphoma of the central nervous system (primary CNS lymphoma; CNS DLBCL) (abstract 2009), a primary CNS malignancy distinct from systemic/nodal DLBCL with its own staging and CNS-directed treatment paradigm. The setting expands the tislelizumab franchise beyond solid tumors into primary CNS lymphoma specifically; it should not be read as a systemic-DLBCL indication. Both sessions deepen biomarker-defined and cross-class evidence rather than expand into new solid-tumor types — consistent with franchise maturation.
• SystImmune SystImmune holds five high-tier ASCO sessions over 48 hours. Two Oral Abstracts: BL-M14D1 (a DLL3-directed ADC) in SCLC and other solid tumors, Phase I (abstract 3001); T-Bren / BL-M07D1 in recurrent/metastatic ovarian cancer, Phase II (abstract 3003). One Late-Breaking Oral: LBA1003, izalontamab brengitecan (iza-bren) versus physician's choice of chemotherapy in unresectable locally advanced or metastatic triple-negative breast cancer (TNBC), Phase III. One Oral Abstract: iza-bren versus chemotherapy in recurrent or metastatic esophageal squamous cell carcinoma (ESCC) (abstract 4008). One Rapid Oral: SI-B001 (the EGFR × HER3 bispecific antibody scaffold) plus paclitaxel or docetaxel in recurrent/metastatic head and neck cancer (abstract 6019). SystImmune is privately held; R&D operations in Bothell, Washington and Beijing.
• Hengrui Oral Abstract 3505 (Sunday morning) reports a Phase 3 of SHR-A1811 (trastuzumab rezetecan), Hengrui's HER2-targeting antibody-drug conjugate, against standard of care in chemotherapy-refractory HER2-positive advanced colorectal cancer. Regulatory status: trastuzumab rezetecan received first approval from China's NMPA on May 29, 2025, for HER2-mutant non-small cell lung cancer; the U.S. FDA granted Orphan Drug Designation in August 2025 for the asset in combination with adebrelimab and chemotherapy in gastric/gastroesophageal junction adenocarcinoma. Hengrui licensed worldwide rights (excluding mainland China, Hong Kong, Macau, Taiwan, USA, Canada, Europe, Japan, Russia, and the CIS/Eurasian markets (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan)) to Glenmark Pharmaceuticals in September 2025. A U.S. filing in the colorectal indication has not been disclosed.
• 2024–25
  licensing cohort First ASCO cycle in which the 2024–2025 out-licensing vintage can be evaluated as a cohort. Tracked transactions with publicly disclosed total deal values include: Innovent → Takeda multi-asset (IBI343 + IBI363 + IBI3001; $1.2B upfront, up to $11.4B total, October 2025); 3SBio → Pfizer SSGJ-707 ($1.25B upfront + $100M equity, up to ~$6B total, May 2025); Hengrui → GSK 12-program platform ($500M upfront across agreements, up to ~$12B total, July 2025). Other 2024–2025 deals with partial disclosure: LaNova → Merck & Co. LM-299 ($588M upfront, total undisclosed, November 2024); Hengrui → Merck & Co. HRS-5346 oral Lp(a) ($200M upfront, up to ~$2B total, March 2025); CSPC → AstraZeneca YS2302018 Lp(a) ($100M upfront, ~$2B total, October 2024); Hengrui → Glenmark Pharmaceuticals SHR-A1811 (September 2025; $18M upfront, up to $1.093B in milestones plus royalties, per primary disclosures). 2026 post-period comparator (outside the cohort): CSPC → AstraZeneca obesity and T2D portfolio (8 programs led by SYH2082), announced January 30, 2026 — $1.2B upfront; up to $3.5B in development and regulatory milestones; up to $13.8B in sales milestones; total potential value up to $18.5B. Cumulative disclosed total deal value across publicly-quantified 2024–2025 transactions in the cohort exceeds $35 billion.

Coverage spans ASCO Annual (May/June), ESMO Congress (September/October), AACR Annual (April), and ASH Annual (December). Each reported count states the comparison set against which it is calculated and cites the underlying source document. Abstracts authored by Western licensees on Chinese-origin assets are attributed to the originating sponsor through the asset-name match path; commercial ownership of the asset remains with the originator.

§1 Setup: Western comparators, U.S. and China policy variables, and the regulatory framework for Chinese-origin trial data

Each of the five topics above sits within a specific Western competitive context and is shaped by U.S.-side or China-side policy variables. Supporting detail on each policy lever follows in the four subsections after the matrix.

1.1 The BIOSECURE Act and its second-order effect on in-licensing

The BIOSECURE Act, signed into law on December 18, 2025 as Section 851 of the FY2026 National Defense Authorization Act, restricts U.S. federal contracts and grants with “biotechnology companies of concern” (BCCs). The enacted statute does not explicitly name specific entities; instead, it relies on two designation mechanisms: (i) automatic designation through the Department of Defense Section 1260H list of Chinese military companies, and (ii) a criteria-based interagency process administered by the Office of Management and Budget. Earlier draft versions had named WuXi AppTec, WuXi Biologics, BGI, MGI, and Complete Genomics; none of these is currently designated as a BCC under the enacted law, though on the day of signing, Senate and House committee chairs sent a letter to DoD recommending the WuXi entities be added to the 1260H list. None of the five topics discussed in this issue involves an entity currently designated as a BCC. The structurally important effect of the Act on this dataset is indirect: due-diligence pipelines at large U.S. and European pharmaceutical companies now treat in-licensing of a fully characterized Chinese-origin asset as a lower-risk pathway than contracting with a Chinese contract manufacturer (CDMO) or contract research organization (CRO) for development. This explains why the 2024–2025 out-licensing cohort is concentrated by transaction value rather than dispersed across smaller research-stage deals.

1.2 FDA precedent on China-only pivotal data

On February 10, 2022, the FDA Oncologic Drugs Advisory Committee (ODAC) voted 14–1 that an additional clinical trial should be conducted before the FDA considered approval of sintilimab (Innovent’s PD-1 monoclonal antibody) for first-line non-squamous non-small cell lung cancer. The vote identified three concerns with the pivotal ORIENT-11 trial: single-country (China-only) design, comparator regimen not reflecting U.S. standard therapy, and the sponsor’s decision not to use overall survival as the primary endpoint. This is the central FDA precedent for Chinese-origin oncology applications relying on single-region China data. Two subsequent approvals demonstrate the recovery pathway: toripalimab-tpzi (Junshi’s PD-1 mAb, licensed in the U.S. to Coherus as Loqtorzi) received FDA approval on October 27, 2023, for first-line metastatic or recurrent locally advanced nasopharyngeal carcinoma (in combination with cisplatin and gemcitabine) and as a single agent for recurrent unresectable or metastatic NPC with disease progression on or after platinum-containing chemotherapy. Tislelizumab-jsgr (BeOne’s PD-1 mAb; brand Tevimbra) received U.S. approvals on March 14, 2024, as monotherapy for unresectable or metastatic ESCC after prior systemic chemotherapy, and on March 4, 2025, for first-line unresectable or metastatic esophageal squamous cell carcinoma with PD-L1 expression (in combination with platinum-based chemotherapy). Three questions read into ASCO 2026 from this precedent set: (i) the eventual U.S. regulatory pathway for trastuzumab rezetecan (NMPA-approved May 2025 for HER2-mutant NSCLC; FDA Orphan Drug Designation August 2025 in gastric/GEJ; no public U.S. BLA acceptance disclosed); (ii) the timing and readout of HARMONi-3 (Akeso/Summit’s globally enrolling Phase 3 of ivonescimab + chemotherapy versus pembrolizumab + chemotherapy in 1L NSCLC) — the squamous-cohort interim PFS analysis on April 30, 2026 missed the early-significance bar, the iDMC recommended continuation, and final PFS is expected in 2H 2026; and (iii) how the FDA reads the HARMONi-6 result (LBA4 at this meeting: ivonescimab + chemotherapy versus tislelizumab + chemotherapy in squamous NSCLC, run at Chinese sites; OS readout) as supportive evidence for the HARMONi-3 package. The narrower ivonescimab U.S. filing is already in front of the FDA via the global Phase III HARMONi trial (ivonescimab + chemotherapy in EGFR-mutated non-squamous NSCLC after prior EGFR-TKI therapy); the BLA has been accepted and the PDUFA target action date is November 14, 2026 — the first U.S. regulatory decision point for the asset and a discrete catalyst separate from HARMONi-3. Sintilimab’s subsequent partial recovery establishes that the regulatory pathway exists; the practical question is whether each new Chinese-origin asset spends two to three years navigating it.

1.3 Single-region trust by topic

Investor cross-checks on Chinese-origin trial data now typically begin with a single question: even if the data are statistically valid, will the regulatory agencies and Western buy-side investors treat them as sufficient. Empirically, single-region China data is not independently sufficient to support FDA approval in most settings, but the magnitude of the “single-region discount” varies. Three variables move the discount: (a) the prevalence and epidemiology of the disease (rare diseases or diseases with regional concentration receive more flexibility), (b) the availability of established U.S. comparators (where a U.S. standard of care exists, the FDA requires U.S.-relevant data on the candidate against that standard), and (c) whether a parallel globally enrolling trial is in progress (which provides a confirmatory pathway). The five topics of this issue are assessed against this framework below:

“Trusted” means different things by audience: FDA remains skeptical of China-only in U.S.-common diseases with established U.S. comparators, open in rare diseases and when a parallel global trial is running. EMA is more accepting on GCP-inspected data — approved tislelizumab and toripalimab before FDA in their respective indications. NMPA accepts at full weight. BD&L takes China data as mechanism validation and prices the deal assuming U.S./global trial spend post-close. Buy-side divides: single-region risk is the explicit hedge most pre-ASCO notes flagged after the 2022 sintilimab vote.

U.S. FDA approval typically requires more than China-only Phase 3 data. The Chinese-origin assets in this issue sit at different points on that pathway. SHR-A1811 is NMPA-approved in China (HER2-mutant NSCLC, May 2025), has U.S. Orphan Drug Designation in gastric/GEJ (August 2025), and has been licensed by Hengrui to Glenmark for development outside Hengrui's retained territories; a U.S. BLA submission has not been publicly disclosed. Ivonescimab: the FDA has accepted Summit’s BLA via the global Phase III HARMONi trial in EGFR-mutated non-squamous NSCLC after prior EGFR-TKI therapy, with a PDUFA target action date of November 14, 2026 (the first U.S. regulatory decision point for the asset). The broader 1L NSCLC U.S. pathway is HARMONi-3 (vs pembrolizumab + chemotherapy, globally enrolling): squamous-cohort interim PFS missed the early-significance bar on April 30, 2026, the iDMC recommended continuation, and final PFS is expected in 2H 2026 (interim OS analyses planned). HARMONi-6 (the LBA4 readout: vs tislelizumab, squamous, Chinese sites) is supportive evidence for HARMONi-3 but does not on its own support a U.S. filing. The catalysts above are ordered by regulatory proximity to the U.S. market.

1.4 China-side pricing pressure and the out-licensing supply

The annual National Reimbursement Drug List (NRDL) price negotiation, administered by China’s National Healthcare Security Administration, has progressively compressed in-China prices on PD-1 monoclonal antibodies, HER2-targeting antibody-drug conjugates, and most other oncology categories to a fraction of U.S. and European levels. The Volume-Based Procurement (VBP) program, a parallel tendered-purchase mechanism, has applied additional downward pressure across multiple rounds. In aggregate, Chinese oncology revenue per unit has declined to levels at which domestic sales alone do not support the cost of next-generation pipeline development for most Chinese pharmaceutical companies. The 2024–2025 out-licensing cohort reads as a direct response to this revenue compression: Chinese sponsors require ex-China revenue at Western pricing to sustain pipeline reinvestment. CSPC Pharmaceutical Group’s sequential deals with AstraZeneca (the Lp(a) inhibitor YS2302018 in October 2024 with $100M upfront and up to ~$2B total; and, as a 2026 post-period extension of the same pattern, the eight-program obesity and T2D portfolio led by SYH2082, announced January 30, 2026 with $1.2B upfront, up to $3.5B in development and regulatory milestones, and up to $13.8B in sales milestones, for total potential value up to $18.5B) and Hengrui’s parallel out-licensing book (transactions with Merck & Co. on HRS-5346, with Kailera Therapeutics on its oral GLP-1 portfolio, with GSK on a twelve-program platform, and with Glenmark Pharmaceuticals on trastuzumab rezetecan) illustrate this pattern at the largest scale.

§2 Historical abstract footprint by sponsor and by meeting, 2018–2026

ASCO-only year-over-year changes, 2025 → 2026: BeOne Medicines from 61 to 90 (a new tracked peak); Akeso from 18 to 43 (a 2.4× increase, attributable primarily to expanded ivonescimab clinical-program output and to combination work on cadonilimab); Junshi from 23 to 43 (new peak); Innovent from 35 to 41 (new peak); HUTCHMED from 35 to 39 (new peak). Hengrui registered a small decline (53 to 50), consistent with the plateau observed since 2021. RemeGen declined from 26 to 20, its first ASCO-cycle step-back since the 2023 expansion of disitamab vedotin reporting. 3D Medicines registered zero Chinese-attributed abstracts at ASCO 2026, the continuation of an output collapse that began in 2023 (further detail in §7).

The three other meetings shown below have not yet occurred in 2026, so each panel terminates at 2025. ESMO Congress 2026 is scheduled for October 23–27 at IFEMA Madrid and is the next major data window for this cohort. AACR Annual 2026 took place in spring 2026; its Chinese-attribution counts have not yet been pulled into this dataset. ASH Annual 2026 occurs in December.

2.2 How we count: direct affiliation versus via-asset attribution

The trajectory chart above counts an abstract as Chinese-attributed when either condition holds: (a) at least one author lists a Chinese pharmaceutical sponsor as their affiliation (direct attribution), or (b) the abstract names a Chinese-origin asset (a drug whose intellectual property originated with a Chinese sponsor) in its title or body, regardless of who authored it (via-asset attribution). The combined measure is what the apples-to-apples chart above tracks, and that measure is rising. The composition between the two paths, however, has shifted substantially: a large share of Chinese-attributed abstracts in 2024–2025 enter the dataset via the asset-mention path rather than via direct affiliation, indicating that academic medical centers and Western licensees (rather than the originator company itself) are increasingly the parties authoring published work on Chinese-origin assets.

Quantification: among 2024–2025 abstracts attributable to Shanghai Junshi Biosciences, 97% reach the dataset via mentions of toripalimab in third-party abstracts; only 3% are authored under Junshi’s direct affiliation. Analogous shares for other sponsors: Akeso 93% via-asset, RemeGen 91%, HUTCHMED 87%, Innovent 84%, Hengrui 75%, BeOne 73%. The chart below visualizes this split. §7 returns to the structural implications of this attribution shift.

§3 Year-over-year change in abstract output: cross-conference (2024–2025) and ASCO-only (2025–2026)

The left panel measures change between 2024 and 2025 across all four meetings combined. The right panel measures change between ASCO 2025 and ASCO 2026 alone. Rankings differ across the two measures. Shanghai Henlius Biotech posted the largest cross-conference increase at +150% but produced no Chinese-attributed abstract at ASCO 2026; its growth was concentrated outside ASCO. Akeso posted the largest ASCO-only increase at +139% against a depressed 2023 ASCO baseline.

ASCO 2026 represents a significant step-change in abstract output for sponsors whose ASCO presence was depressed in 2023, notably Akeso and Shanghai Junshi. The 2024–2025 cross-conference dataset had already identified two sponsors posting large percentage increases from small absolute bases (Shanghai Henlius and Alphamab Oncology); both warrant continued tracking into ESMO Congress 2026 in October.

Not represented on the ASCO panel (no 2025 ASCO base): SystImmune presents seven ASCO 2026 abstracts, all de novo. Alphamab presents two. Both are first-time ASCO presences for these sponsors in the tracked period and are scheduled for promotion to the canonical sponsor table for the post-ASCO 2026 edition.

§4 ASCO 2026 program composition: Chinese-attributed abstracts by session type, asset, and sponsor

Of the 7,295 abstracts published in the ASCO 2026 meeting program, 298 (4.1%) reference a Chinese-origin sponsor or asset in their title or body text. One of these is in the Plenary Session, the meeting’s highest-tier slot. Composition by session type, asset, and timeline follows in the subsections below.

4.1 The Plenary slot: Late-Breaking Abstract 4 (LBA4)

Distribution of Chinese-attributed presentations by session type:

By asset, ranked by total abstract-body mention count across the program — with phase(s) and top indication(s) extracted from the abstract bodies:

Phase distribution and indication tags extracted from abstract titles and bodies (first 600 chars). Synonyms are collapsed within a single molecule only: cadonilimab/AK104; ivonescimab/AK112; disitamab vedotin/RC48; izalontamab brengitecan (iza-bren)/BL-B01D1. SI-B001 (izalontamab) is the unconjugated EGFR×HER3 bispecific antibody scaffold of iza-bren and is carried as a related but distinct entry. BL-M07D1 (T-Bren) is a separate antibody-drug conjugate — not an iza-bren alias — and, with BL-M14D1 (DLL3 ADC) and BL-M05D1 (CLDN18.2 ADC), is tabulated as an independent asset. ESCC and esophageal counted separately when the abstract used both. Counts are per asset.

4.4 Emerging sponsors: first high-tier ASCO presentations from Chinese-origin pharma

AssayOne tracks 58 Chinese-origin pharmaceutical sponsors. Eight of these are flagged here as “emerging”: companies presenting in a high-tier ASCO session (Oral Abstract, Rapid Oral, Clinical Science Symposium, or Late-Breaking) for the first time in the tracked period. The historical attribution for each is being back-filled across ASCO Annual, ESMO Congress, AACR Annual, and ASH Annual for the post-ASCO 2026 edition. The editorial rule is that any Chinese-origin sponsor with a confirmed high-tier presentation at a major annual oncology meeting is added to the tracked set in the cycle of first appearance, with historical counts back-filled within the same edition or the next.

4.5 High-tier session timeline: every Chinese-attributed Plenary, Oral, Rapid Oral, and Clinical Science Symposium slot, with originator and observation note

Sorted chronologically. All times Central Time, Chicago. The “Sponsor” column names the originator (and licensee where the licensee is presenting). The “Watch” line is the specific data point that determines whether the session matters for the franchise.

4.6 Five observations on the program composition

(i) SystImmune’s high-tier slot allocation is disproportionate to its public profile. SystImmune holds five high-tier ASCO 2026 sessions across 48 hours. Oral Abstract 3001: BL-M14D1, a delta-like ligand 3 (DLL3)-directed antibody-drug conjugate, Phase I, in small-cell lung cancer and other solid tumors. Oral Abstract 3003: T-Bren (BL-M07D1) in recurrent or metastatic ovarian cancer, Phase II. Oral Abstract 4008: izalontamab brengitecan (iza-bren) versus chemotherapy in recurrent or metastatic esophageal squamous cell carcinoma. Late-Breaking Oral LBA1003: iza-bren versus physician’s choice of chemotherapy in unresectable locally advanced or metastatic triple-negative breast cancer, Phase III. Rapid Oral 6019: SI-B001 (the EGFR × HER3 bispecific antibody scaffold underlying iza-bren) plus paclitaxel or docetaxel in recurrent/metastatic head and neck cancer, Phase II. The pairing of LBA1003 (TNBC) and 4008 (ESCC) within 48 hours establishes the multi-tumor activity profile for the EGFR × HER3 bispecific ADC. SystImmune is privately held, but its lead program is not unpartnered: BL-B01D1 (iza-bren) is licensed to Bristol Myers Squibb for ex-China development and commercialization (see §6), so the iza-bren readouts at this meeting carry directly into a large-cap Western pipeline.

(ii) Hengrui SHR-A1811 (trastuzumab rezetecan): Phase 3 readout against standard of care in HER2-positive advanced colorectal cancer. Oral Abstract 3505, Sunday morning. The asset has the following confirmed regulatory status: NMPA approval in China (May 29, 2025) for HER2-mutant non-small cell lung cancer; U.S. FDA Orphan Drug Designation (August 2025) for use in combination with adebrelimab and chemotherapy in gastric or gastroesophageal junction adenocarcinoma; and a worldwide ex-territory license to Glenmark Pharmaceuticals (September 2025). A U.S. BLA submission for trastuzumab rezetecan has not been publicly disclosed. The colorectal Phase 3 reported in Oral Abstract 3505 represents one of multiple indications under development. The comparator class for HER2-targeting ADCs is Daiichi Sankyo / AstraZeneca trastuzumab deruxtecan (Enhertu).

(iii) Akeso cadonilimab (AK104, PD-1/CTLA-4 bispecific antibody): positioned as a combination-backbone agent. Cadonilimab appears in 24 ASCO 2026 abstracts, including an opening-day Oral Abstract session (4501, cadonilimab + axitinib in first-line advanced non-clear cell renal cell carcinoma). Cadonilimab combinations span partner classes: axitinib (a VEGF receptor tyrosine kinase inhibitor); fruquintinib (HUTCHMED’s VEGFR-1/2/3 inhibitor); ivonescimab (Akeso’s own PD-1/VEGF bispecific); and disitamab vedotin (RemeGen’s HER2 antibody-drug conjugate). The breadth of combination partners suggests Akeso is positioning AK104 as a PD-1/CTLA-4 combination backbone — a platform agent that other Chinese sponsors’ pipeline assets are tested against or in combination with. This pattern is consistent with deliberate ecosystem positioning rather than incidental co-development.

(iv) BeOne tislelizumab: biomarker-defined and cross-class evidence beyond the Plenary. Two Rapid Oral sessions cover the asset outside the Plenary: a biomarker-stratified perioperative trial in gastric / gastroesophageal junction adenocarcinoma enrolling both tsMHC-II-positive and tsMHC-II-negative cohorts (abstract 2513), and the KCSG-sponsored SPECTRUM trial (LY22-07) using BeOne's tislelizumab + pemetrexed in relapsed/refractory primary diffuse large B-cell lymphoma of the central nervous system (primary CNS lymphoma; CNS DLBCL) (abstract 2009) — a primary CNS malignancy distinct from systemic/nodal DLBCL, with its own staging and CNS-directed treatment paradigm, that expands the tislelizumab franchise beyond solid tumors into primary CNS lymphoma specifically (not a systemic-DLBCL indication). The selection of session content indicates BeOne is using ASCO 2026 to add evidence supporting tislelizumab in biomarker-defined subsets and in adjacent malignancy classes rather than to broaden indication labels in approved solid-tumor types. This pattern is consistent with mid-franchise asset development — building depth of supportive evidence around an approved indication — rather than with early-franchise expansion.

(v) Intra-China combination studies: a pattern underrepresented in published analyst coverage. Multiple ASCO 2026 abstracts pair assets from two different Chinese sponsors in a single trial design: cadonilimab + disitamab vedotin (or + nab-paclitaxel by HER2 IHC cohort) in recurrent/metastatic cervical cancer, Phase II (Akeso × RemeGen, abstract 5526); fruquintinib + sintilimab in previously treated advanced renal cell carcinoma, FRUSICA-2 subgroup/post-hoc analyses (HUTCHMED × Innovent, abstracts 4531 and 4533); SHR-A1811 + chemotherapy + BP102 (Hengrui’s bevacizumab biosimilar) as first-line therapy in HER2-expressing metastatic colorectal cancer, Phase Ib/II (abstract 3569). These are intra-China combinations rather than the more familiar licensee-driven combinations of Chinese-origin assets with Western immune-oncology backbones. The pattern indicates the Chinese oncology pipeline has reached sufficient density for in-China clinical development to run head-to-head pivotal studies internally, without Western partnership. This is a different competitive structure than the “Chinese sponsor licensing to Western pharma” narrative that dominates published sell-side coverage of the cohort.

§5 Asset profiles: development status, indications, and ASCO 2026 presentation slots

These are the assets with material data expected at Chicago, ranked here by total title-mentions across the historical data. Some are mature (tislelizumab, camrelizumab); others are early in their conference-publication cycle (HLX22, IBI343).

5.1 Akeso ivonescimab (AK112) — PD-1/VEGF bispecific antibody; ex-China rights to Summit Therapeutics

Ivonescimab is the first Chinese-originated programmed death-1 (PD-1) / vascular endothelial growth factor (VEGF) bispecific antibody to reach late-stage clinical development. Its U.S. status is best read as three concurrent tracks, not a single pending catalyst. Track A — near-term, narrow. The global Phase III HARMONi trial in EGFR-mutated non-squamous NSCLC after prior EGFR-TKI therapy supports an accepted Summit BLA with a PDUFA target action date of November 14, 2026 — the first U.S. regulatory decision point for the asset and one that lands inside this report’s forward calendar window. Track B — broad, franchise-defining. The HARMONi-3 trial (ivonescimab + chemotherapy vs pembrolizumab + chemotherapy in 1L NSCLC; globally enrolling including U.S. sites) is the broader U.S.-pathway trial; on April 30, 2026 the squamous-cohort interim PFS analysis missed the early-significance bar, the iDMC recommended the study continue, Summit’s shares declined approximately 26% on the news, final squamous PFS is expected in 2H 2026, and the non-squamous final readout is expected in 1H 2027. Track C — supportive / China. HARMONi-2 (n=398, China; ivonescimab 20 mg/kg monotherapy vs pembrolizumab 200 mg q3w; first-line PD-L1-positive [TPS ≥1%] advanced NSCLC; EGFR/ALK negative) reported median PFS 11.14 vs 5.82 months, HR 0.51 (P<.0001) at the 2024 World Conference on Lung Cancer. HARMONi-6 (ivonescimab + chemotherapy vs tislelizumab + chemotherapy in previously untreated advanced squamous NSCLC; Chinese sites; PFS positive) reads out OS at LBA4 of this meeting. Post-April-30, LBA4 functions as a cross-read on the HARMONi-3 squamous interim miss: same drug, same histology, different comparator (tisle vs pembro) and different geography (China-only vs global). The interpretive question — comparator strength versus China-vs-global population effect (cf. the Asian-subset PFS differential in the HARMONi EGFR data) — is now the principal near-term driver of the broad 1L U.S.-commercial case. Title-mention counts: 19 across the four annual meetings 2018–2025; 22 in the ASCO 2026 program via combined title-and-body matching. ASCO 2026 footprint also includes Oral Abstract 8007 (ivonescimab + liposomal irinotecan in SCLC) and Rapid Oral 6014 (neoadjuvant ivonescimab + nab-paclitaxel + cisplatin in resectable locally advanced head and neck cancer). Summit Therapeutics is licensed for ex-China commercialization and conducts U.S. trial enrollment; Summit-authored abstracts are attributed to the originator via the asset-mention path.

5.2 Hengrui SHR-A1811 (trastuzumab rezetecan) — HER2-targeting antibody-drug conjugate

Trastuzumab rezetecan (development code SHR-A1811) is Hengrui’s HER2-targeting antibody-drug conjugate, comprising a trastuzumab antibody backbone linked to a topoisomerase I inhibitor payload. Title mentions: 18 across the four annual meetings 2022–2025. Regulatory status as of issue date: NMPA approval in China (May 29, 2025) for HER2-mutant non-small cell lung cancer; U.S. FDA Orphan Drug Designation (August 2025) for the asset in combination with adebrelimab and chemotherapy in gastric or gastroesophageal junction adenocarcinoma; worldwide ex-territory license to Glenmark Pharmaceuticals (September 2025; territories retained by Hengrui include mainland China, Hong Kong, Macau, Taiwan, the United States, Canada, Europe, Japan, Russia, and the CIS/Eurasian markets (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan)). No U.S. BLA submission has been publicly disclosed. The ASCO 2026 footprint centers on Oral Abstract 3505 (Sunday morning), reporting Phase 3 trastuzumab rezetecan versus standard of care in chemotherapy-refractory HER2-positive advanced colorectal cancer. Additional Phase 2 and Phase 1b/2 data on HR-positive / HER2-low breast and combination regimens appear elsewhere in the meeting. The competitive comparator class for HER2-targeting ADCs is Daiichi Sankyo / AstraZeneca’s Enhertu (trastuzumab deruxtecan).

5.3 Innovent IBI343 — Claudin 18.2 antibody-drug conjugate; ex-China rights to Takeda

IBI343 is Innovent’s Claudin 18.2 (CLDN18.2)–targeting antibody-drug conjugate. In October 2025, Innovent announced a multi-asset global strategic partnership with Takeda covering IBI343 plus IBI363 (PD-1 / IL-2α-bias bispecific) plus IBI3001 (option) for ex-Greater China rights, with $1.2 billion upfront (including $100M premium equity) and up to $11.4 billion in total deal value (including up to ~$10.2 billion in development and sales milestones). Title mentions for IBI343: 4 across the historical period — characteristic of an asset still early in its conference-publication cycle. The ASCO 2026 program does not include an Oral or Rapid Oral slot for IBI343; data flow at the meeting is at the Poster and Publication-Only levels. The structural item to track is the eventual first Takeda-authored presentation. CLDN18.2 antibody-drug conjugate development is now a Chinese-led therapeutic class (see §7.3): IBI343, LaNova LM-302 (licensed to Turning Point Therapeutics, acquired by Bristol Myers Squibb), and SystImmune BL-M05D1 are the principal active programs and will read in overlapping data windows.

5.4 Innovent IBI363 — PD-1 / IL-2α-bias bispecific antibody; Innovent-developed, no ex-China licensee

IBI363 is a bispecific antibody combining PD-1 blockade with an interleukin-2 (IL-2) α-bias variant, intended to focus IL-2 stimulation on PD-1-positive immune cells. Innovent retains the asset internally; there is no ex-China licensee. Title mentions: 8 across 2024–2025. Innovent has previously stated that full Phase 1b data for IBI363 will be presented at ESMO Congress 2026 (Madrid, October) rather than at ASCO. The ASCO 2026 program includes three IBI363 abstracts (two Phase 1, one Phase 3) in small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), all preliminary rather than central readouts.

5.5 HUTCHMED fruquintinib (HMPL-013, Fruzaqla) — VEGFR-1/2/3 tyrosine kinase inhibitor; ex-China rights to Takeda

Fruquintinib is HUTCHMED’s selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3. The asset received U.S. FDA approval in 2023 for previously treated metastatic colorectal cancer under the brand name Fruzaqla. Title mentions: 102 across 2018–2025, the second-highest in HUTCHMED’s portfolio. The ASCO 2026 footprint contains 30 abstracts, dominated by Phase 2 and Phase 3 work in metastatic colorectal, gastric, and esophageal cancers. Post-2023 expansion of the dataset reflects Takeda-led extension cohorts. A related HUTCHMED asset to track is savolitinib (Orpathys, a selective MET inhibitor; ex-China rights to AstraZeneca): Rapid Oral 4011 at ASCO 2026 will be the first session in the meeting in which a tracked Western licensee (AstraZeneca) authors a pivotal Phase 2 readout for a Chinese-origin asset.

5.6 BeOne tislelizumab (PD-1 mAb) and zanubrutinib (BTK inhibitor) — the two anchor assets

Tislelizumab-jsgr is BeOne’s PD-1 monoclonal antibody, marketed as Tevimbra; U.S. FDA approvals are for esophageal squamous cell carcinoma (ESCC): first-line in combination with platinum-based chemotherapy in PD-L1-positive disease (March 4, 2025) and as monotherapy after prior chemotherapy (March 14, 2024). Zanubrutinib is BeOne’s Bruton’s tyrosine kinase (BTK) inhibitor, marketed as Brukinsa; first U.S. FDA approval in November 2019 for mantle cell lymphoma. Title mentions in this dataset: 335 for tislelizumab and 258 for zanubrutinib across 2018–2025, the two highest counts among Chinese-origin assets. The ASCO 2026 footprint includes the Plenary slot (LBA4 versus ivonescimab), Rapid Oral sessions in biomarker-stratified perioperative gastric / GEJ adenocarcinoma (abstract 2513, enrolling both tsMHC-II-positive and tsMHC-II-negative cohorts) and the KCSG-sponsored SPECTRUM trial (LY22-07) in relapsed/refractory primary diffuse large B-cell lymphoma of the central nervous system (abstract 2009 — tislelizumab + pemetrexed; primary CNS lymphoma / CNS DLBCL, distinct from systemic/nodal DLBCL), the Late-Breaking Rapid Oral on rectal chemo-radiotherapy with tislelizumab (LBA3515, Tuesday), and the BGB-B2033 Phase 1 (abstract 3016, a glypican-3 (GPC3) × 4-1BB bispecific antibody representing BeOne’s pipeline beyond tislelizumab). Zanubrutinib output is concentrated at ASH (hematology meeting). BeOne’s 90 ASCO 2026 Chinese-attributed abstracts represent the highest single-meeting count in the tracked period (61 at ASCO 2025).

5.7 Shanghai Henlius HLX22 — anti-HER2 monoclonal antibody, Phase 3 in 2026

HLX22 is Shanghai Henlius Biotech’s anti-HER2 monoclonal antibody. The company’s disclosed pipeline includes a Phase 3 readout for HLX22 in 2026. Title mentions to date: 2 across 2018–2025 (early). The ASCO 2026 program does not include a Chinese-attributed Henlius slot in the body-plus-title scan. ESMO Congress 2026 (October, Madrid) is the more likely first-look venue. Henlius’s cross-conference output increased 150% from 2024 to 2025; that growth rate carries forward as a cohort-level signal into ESMO.

5.8 Junshi toripalimab (Loqtorzi) — PD-1 monoclonal antibody; ex-China U.S. rights to Coherus

Toripalimab-tpzi is Shanghai Junshi Biosciences’s PD-1 monoclonal antibody, marketed in the U.S. as Loqtorzi. It became the first Chinese-originated PD-1 monoclonal antibody to receive U.S. FDA approval, on October 27, 2023: in combination with cisplatin and gemcitabine for first-line metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC), and as a single agent for recurrent unresectable or metastatic NPC with disease progression on or after platinum-containing chemotherapy. Title mentions: 225 across 2018–2025. Coherus BioSciences holds U.S. and Canada commercialization rights and has authored U.S.-relevant data on the asset since 2024. The ASCO 2026 footprint includes 42 toripalimab abstracts; two Rapid Oral sessions are detailed in the §4 schedule (perioperative NSCLC, abstract 8010; maintenance combination, abstract 11512).

§6 Out-licensed assets: Chinese-origin programs developed by Western pharma partners

A subset of Chinese-origin assets is now developed primarily by international licensees rather than by the originating Chinese sponsor. Where Takeda, Summit Therapeutics, Coherus BioSciences, or other Western partners present clinical data on a licensed asset, the publication author affiliations identify the licensee, not the originator. The dataset attributes such abstracts to the originator via the asset-name match path, since the asset itself remains the originator’s commercial property and clinical-development output is the originator’s long-term value driver.

Deal terms for the tracked licensing arrangements. Values shown are as disclosed in originator or counterparty press releases or SEC filings. Where a figure is not available in a primary source, the cell reads “n/a.” Rows involving 2026 post-period comparators are retained for context but are not included in the 2024–2025 cohort total.

Specific items to track at ASCO 2026 within this licensee-led pathway: any Takeda-authored IBI343 (Claudin 18.2 ADC) or fruquintinib presentation; AstraZeneca-authored savolitinib (MET inhibitor) or SYS6010 (EGFR ADC) data; Summit Therapeutics-authored ivonescimab data. The post-ASCO 2026 edition will flag the first ASCO session in which a tracked Western licensee leads on the byline of a Chinese-origin asset.

§7 Structural observations: patterns visible at the dataset level that are not reflected in sponsor-by-sponsor reporting

7.1 Originator-authored output is now a minority share of attribution for five of seven mature Chinese-origin oncology franchises

For five of the seven mature Chinese-origin oncology franchises tracked in this dataset, abstracts authored under the sponsor’s own organizational affiliation now represent a minority share of total Chinese-attributed output. The parties authoring abstracts on a given asset are the parties shaping the academic and clinical conversation around that asset — selecting trial sites, working with key opinion leaders, and constructing the combination-therapy narrative. When 97% of 2024–2025 toripalimab attribution comes through clinical sites unaffiliated with Junshi Biosciences, Junshi’s ability to control the asset’s academic positioning is materially constrained relative to the period in which it authored the majority of trials. The same pattern applies, in varying degrees, to four other sponsors:

Coherus BioSciences authors U.S. presentations of toripalimab; Summit Therapeutics authors ex-China presentations of ivonescimab; Takeda authors fruquintinib presentations and is expected to begin authoring IBI343 presentations in the next reporting cycle. The originating Chinese sponsors continue to respond to investor questions about these assets on their respective earnings calls, but the parties who produce the data and lead the academic discussion are organizationally separate from those sponsors. This is a structural feature of the cohort that is rarely characterized explicitly in sponsor-by-sponsor reporting.

7.2 3D Medicines: a tracked case of cross-conference output collapse, with implications for screening methodology

3D Medicines (Hong Kong Stock Exchange: 1244.HK) recorded annual cross-conference abstract counts of 47, 46, 69, and 62 across 2019–2022, then 7, 8, and 10 across 2023–2025 — a decline of approximately 87% from the 2021 peak. Among Chinese-origin sponsors with at least 30 abstracts in any single year of the 2018–2022 period, 3D Medicines is the only sponsor whose subsequent output declined by that magnitude. The company’s share-price trajectory on the Hong Kong Stock Exchange tracked the abstract-output decline but lagged the conference signal by approximately one calendar quarter. The implication for methodology is that conference-level abstract counts, monitored in close to real time, can function as an early indicator of sponsor pipeline deterioration before the equity market re-rates the security. The corresponding screening discipline is a quarterly cross-conference output review for sponsors with established conference profiles.

7.3 Claudin 18.2 (CLDN18.2) antibody-drug conjugates: a therapeutic class now dominated by Chinese-origin programs

Claudin 18.2 is a tight-junction protein expressed in a subset of gastric and gastroesophageal junction adenocarcinomas; it has emerged as a therapeutic target distinct from HER2 in the same tumor types. Chinese-origin antibody-drug conjugates targeting CLDN18.2 in active clinical development include: Innovent’s IBI343 (licensed to Takeda as part of the October 2025 multi-asset deal; $1.2B upfront, up to $11.4B total); LaNova’s LM-302 (licensed in 2022 to Turning Point Therapeutics, subsequently acquired by Bristol Myers Squibb; $25M upfront, up to ~$1B total); and SystImmune’s BL-M05D1 (Phase I; first disclosed in the ASCO 2026 program). The principal Western program in the class is Astellas’s zolbetuximab (Vyloy; a Claudin 18.2 monoclonal antibody), FDA-approved October 18, 2024 for first-line locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma whose tumors are CLDN18.2-positive. ASCO 2026 is the first major meeting in which multiple Chinese-origin Claudin 18.2 ADCs will read data within the same conference window.

7.4 The 2024–2025 out-licensing cohort: deal-value concentration that has not been characterized as a single event in published coverage

Several of the largest Chinese-origin oncology and metabolic cross-border licensing deals on record were announced within an approximately twelve-month window spanning late 2024 through 2025: LaNova LM-299 (PD-1/VEGF bispecific antibody) to Merck & Co. (November 2024, $588 million upfront, total undisclosed); Hengrui HRS-5346 (oral Lp(a) inhibitor) to Merck & Co. (March 2025, $200 million upfront, up to approximately $2 billion total); CSPC YS2302018 (Lp(a) inhibitor) to AstraZeneca (October 2024, $100 million upfront, up to approximately $2 billion total); 3SBio SSGJ-707 (PD-1/VEGF bispecific antibody) to Pfizer (May 2025, $1.25 billion upfront plus $100 million equity, up to approximately $6 billion total — the largest single-deal upfront on record for a Chinese-origin biotech asset); Innovent IBI343 plus IBI363 plus IBI3001 (multi-asset) to Takeda (October 2025, $1.2 billion upfront including $100M premium equity, up to $11.4 billion total); and Hengrui twelve-program platform to GSK (July 2025, $500 million upfront across agreements, up to approximately $12 billion total). As a 2026 post-period comparator outside the 2024–2025 cohort, CSPC’s eight-program obesity and type 2 diabetes portfolio led by SYH2082 was licensed to AstraZeneca on January 30, 2026, with $1.2 billion upfront and total potential consideration up to $18.5 billion. The pre-2024 baseline rate for cross-border deals of this magnitude was one to two per year. Three plausible drivers operated simultaneously across the cohort: (a) compressed valuation multiples on the Chinese side following the 2021–2023 China-biotech equity drawdown; (b) anticipation of expiring patent protections on Western immune-oncology blockbusters, generating in-licensing demand at the acquirer side; and (c) the BIOSECURE Act’s pending and then realized restrictions on contract development with named Chinese entities, which redirected Western diligence interest from manufacturing partnerships toward finished-asset acquisition. The dataset does not allow isolation of the relative contribution of each driver. This window concentrated the largest cross-border in-licensing decisions from U.S. and European acquirers in the cohort’s recorded history. For context on the prior CLDN18.2 wave: LaNova’s earlier LM-302 (Claudin 18.2 antibody-drug conjugate) was licensed in 2022 to Turning Point Therapeutics (subsequently acquired by Bristol Myers Squibb) at $25 million upfront and up to approximately $1 billion total — a transaction one order of magnitude smaller in upfront than the 2024–2025 deals catalogued above (see §7.3).

7.5 Abstract-mention acceleration as a leading indicator of franchise breakouts: current candidates

The tislelizumab and zanubrutinib trajectories each show an approximately threefold increase in cross-conference title mentions between the 2018–2022 and 2023–2025 periods. Both of these assets have since cleared FDA approval. The same acceleration pattern preceded every Chinese-origin oncology asset that has cleared FDA approval in the period covered by this dataset, supporting the use of cross-conference mention acceleration as a leading indicator of franchise breakout. Three assets in the dataset currently show acceleration of comparable magnitude:

• Cadonilimab (Akeso, PD-1/CTLA-4 bispecific antibody): 6 mentions in 2018–2022 versus 58 mentions in 2023–2025 — an approximately tenfold increase.
• Disitamab vedotin (RemeGen; ex-China rights to Pfizer via Seagen, HER2-targeting antibody-drug conjugate): 14 versus 66 — an approximately fivefold increase.
• Fruquintinib (HUTCHMED, ex-China rights to Takeda; VEGFR-1/2/3 TKI): 19 versus 81 — an approximately fourfold increase, driven principally by Takeda’s post-licensing site expansion.

Ivonescimab’s trajectory of 4 to 13 across the same period is consistent with an earlier-stage version of the same pattern; the asset is the next-tier candidate to monitor on this metric.

The complementary observation is informative: among tracked Chinese-origin assets, savolitinib (HUTCHMED, ex-China rights to AstraZeneca; MET inhibitor) shows a slight decline from 14 to 10 mentions across the same period, and surufatinib (HUTCHMED; VEGFR/FGFR/CSF1R TKI) shows a recent slowing despite a 16-to-49 historical increase. Both are HUTCHMED assets in partnership with AstraZeneca where the conference-output signal has plateaued. This pattern is informationally distinct from the breakout-candidate cohort and warrants separate tracking for HUTCHMED capital-allocation discussions.

§8 Cross-check: published analyst and trade-press views, assessed against the dataset

8.1 Consensus view revisited: ivonescimab as the leading Chinese-origin breakout asset — and what April 30, 2026 changed

Sell-side previews have been treating ivonescimab as the franchise-defining Chinese-origin asset since HARMONi-2 read out positive against pembrolizumab in late 2024. The abstract-trajectory data still support the breakout characterisation as a methodology call: ivonescimab cumulative cross-conference title mentions across 2018–2025 total 19, ASCO 2026 alone adds 22 mentions on the combined title-and-body match, and Akeso’s ASCO-only output more than doubled between 2025 and 2026 (18 to 43 abstracts) — a cumulative trajectory that resembles the early-cycle pattern observed for tislelizumab in 2020–2021, prior to that asset’s commercial breakout. What has changed is not the trajectory; it is the structure of the U.S.-approval narrative attached to it. Pre-meeting analyst coverage has depicted ivonescimab’s U.S. status as “pending, all riding on HARMONi-3, not yet read out.” That description is wrong in both directions simultaneously. The U.S. picture is a three-track story:

• Track A — near-term, narrow approval (likely first). The global Phase III HARMONi trial in EGFR-mutated non-squamous NSCLC after prior EGFR-TKI therapy supports an accepted Summit BLA with a November 14, 2026 PDUFA. This is a discrete, near-term U.S. decision in a defined post-EGFR-TKI niche; it is independent of HARMONi-6 and HARMONi-3. Framing that places ivonescimab as “no U.S. filing yet” understates near-term progress.
• Track B — broad 1L NSCLC U.S. route, materially de-risked downward. HARMONi-3 (ivonescimab + chemotherapy vs pembrolizumab + chemotherapy, globally enrolling including U.S. sites) remains the trial that, if positive, opens the large 1L NSCLC commercial opportunity. On April 30, 2026 the squamous-cohort interim PFS analysis missed the early-significance bar; the iDMC recommended the study continue; Summit shares declined approximately 26% on the news; final PFS is expected in 2H 2026 with interim OS analyses planned. Framing that treats HARMONi-3 as a clean pending catalyst overstates cleanness.
• Track C — HARMONi-6 OS now bears interpretive weight, not just supportive weight. Pre-April-30 framing characterised LBA4 as supportive evidence for HARMONi-3. With HARMONi-3’s squamous interim having missed against pembrolizumab globally, the LBA4 OS readout against tislelizumab in Chinese squamous patients is no longer just a regulatory-supportive datapoint. It becomes the cleanest near-term test of an interpretive question that now governs the asset’s broad 1L U.S.-commercial value: is ivonescimab’s relative performance driven by comparator choice (tisle softer than pembro), by geographic / population effects (China vs global enrollment; an Asian-patient PFS differential analogous to the EGFR-mutated subset literature), or by genuine cross-population activity? A strong OS result in HARMONi-6 favors the comparator-difference reading and keeps the broad 1L thesis intact; a weak or marginal OS result compounds the HARMONi-3 interim and tilts the read toward geographic/population dependence.

Net assessment. The April 30 interim does not collapse the ivonescimab thesis; it bifurcates it. A narrow EGFR-mutated post-EGFR-TKI U.S. approval is now the near-term base case (PDUFA in approximately six months), while the broad 1L NSCLC U.S. opportunity — where the commercial value sits — is materially de-risked downward and now hinges on HARMONi-3 final PFS in 2H 2026 plus the HARMONi-6 OS readout at LBA4. The breakout characterisation remains supported as a methodology call from the trajectory data; the U.S.-approval sub-narrative attached to it is more advanced in one indication and more troubled in the other than pre-meeting coverage depicts.

8.2 Consensus view: the 2024 out-licensing flow represents an inflection in Chinese pharma’s cross-border deal activity

Trade press (Endpoints, Fierce, ChinaBio) framed the 2024 deal flow — Innovent/Takeda, LaNova/Merck, CSPC/AZ, Hengrui/Merck & Co., 3SBio/Pfizer — as inflection. Several reports cited estimates that Chinese-origin assets accounted for the majority of cross-border oncology in-licensing dollars in 2024. Assessment against the dataset. The cohort-level statistics are consistent with this view. Multiple Chinese-origin transactions with disclosed total deal values at or above $5 billion were announced within approximately eighteen months (October 2024 through early 2026), against a pre-2024 baseline of approximately one such transaction per calendar year. The reinforcing data points relative to standard sell-side framing include the GSK / Hengrui twelve-program platform agreement (July 2025; $500 million upfront across the agreements; up to approximately $12 billion in total deal value) and the AstraZeneca / CSPC obesity and type 2 diabetes portfolio, a 2026 post-period comparator announced January 30, 2026, with $1.2 billion upfront and total potential consideration up to $18.5 billion. Publicly disclosed cumulative total deal value across the cohort exceeds $35 billion.

Additional structural context from the dataset. The driver of the deal cohort is not Chinese-side pipeline maturation alone. Three concurrent factors operate on both sides of the negotiations: (a) sustained NRDL price erosion compressing Chinese-side in-China oncology revenue, (b) anticipated U.S./European patent expirations on first-generation immune checkpoint inhibitors driving acquirer demand for replacement assets, and (c) the BIOSECURE Act’s BCC-designation restrictions shifting Western diligence preference toward finished-asset acquisition rather than CDMO partnership. Characterizing the cohort as a Chinese-pharma commercial success understates the structural dependencies on the acquirer side; characterizing it as Western-pharma desperation understates the genuine asset maturation in China. The dataset is more consistent with a synchronized market-clearing event driven by constraints on both sides of the table than with a one-sided narrative.

8.3 Pre-meeting framing: questions raised by published coverage of the HARMONi program

Published coverage of the Akeso/Summit ivonescimab program in advance of ASCO 2026 includes characterisations of LBA4 (HARMONi-6) as a catalyst that would “displace pembrolizumab” in first-line NSCLC. The trial design does not support that characterisation: HARMONi-6 compares ivonescimab + chemotherapy against tislelizumab + chemotherapy in squamous NSCLC at Chinese clinical sites. Pembrolizumab is not on the protocol and the trial is not U.S.-enrolling. A positive HARMONi-6 OS result is commercially material for ivonescimab’s positioning against tislelizumab in China and Europe, and is supportive evidence for the HARMONi-3 dossier; it does not on its own support a U.S. filing.

The separate trial that does compare ivonescimab + chemotherapy against pembrolizumab + chemotherapy is HARMONi-3 (globally enrolling, U.S. sites included); the April 30, 2026 squamous-cohort interim PFS analysis missed the early-significance bar, the iDMC recommended continuation, and final PFS is expected in 2H 2026. Note: ivonescimab’s actual first U.S. filing is via the global Phase III HARMONi trial in EGFR-mutated non-squamous NSCLC post-EGFR-TKI (BLA accepted; PDUFA November 14, 2026) — a discrete catalyst that pre-meeting coverage focused on HARMONi-3 generally omits. Coverage that conflates HARMONi-6 with HARMONi-3, or that treats HARMONi-3 as the only U.S. route, is the principal source of confusion in pre-meeting analyst commentary on the asset.

8.4 Trade-press view: the BIOSECURE Act will reduce U.S.–China cross-border business development activity

Endpoints, STAT, BioCentury all covered the December 18, 2025 signing of BIOSECURE in the FY2026 NDAA as a friction point for U.S.-China life sciences. Some pieces speculated that BIOSECURE would dampen 2026 in-licensing activity. Assessment against the dataset. The evidence supports the opposite conclusion. The BIOSECURE Act, as enacted, restricts U.S. federal contracts and grants with “biotechnology companies of concern” designated through the DoD 1260H list or an OMB-administered process. It does not restrict private U.S. pharmaceutical companies from finished-asset licensing arrangements with Chinese sponsors. The largest disclosed 2024–2025 cohort transaction was the GSK / Hengrui twelve-program platform agreement announced in July 2025. The AstraZeneca / CSPC obesity and type 2 diabetes collaboration, announced January 30, 2026, is better treated as a post-period comparator: it followed the December 18, 2025 BIOSECURE signing and supports the same directional conclusion, but it should not be counted inside the 2024–2025 cohort. The structural pattern is more consistent with the inverse interpretation: BIOSECURE’s restrictions on contract-stage Chinese engagement redirected Western diligence interest toward acquiring finished assets, which are not subject to BCC-designation restrictions. Deal flow has continued and expanded; the post-BIOSECURE window has produced the largest single transactions in the cohort.

Item to monitor in subsequent reporting. The structural question for the next reporting cycle is whether the GSK / Hengrui platform-deal architecture — twelve research programs bundled under a single agreement — becomes a template for subsequent multi-program deals or remains an isolated structure. A repeat of comparable platform deals would indicate a structural shift toward multi-asset acquisition vehicles, which would carry larger implications for Chinese pharma corporate finance than incremental single-asset in-licensing.

Sources noted in this section reflect publicly accessible pre-ASCO coverage from BioSpace, Endpoints, Fierce Pharma, BioCentury, Pharmaceutical Technology, ChinaBio Today, and STAT, plus FDA/EMA/NMPA primary documents. Specific citations expand in the post-ASCO edition. AssayOne does not paraphrase paid sell-side notes; the “consensus view” framings reflect what has been published in the open press.

§9 Late-breaking abstract share by sponsor, 2022–2025 (with ASCO 2026 additions)

A Late-Breaking Abstract (LBA) is an accepted abstract for which data were not available at the standard submission deadline; LBA acceptance at any of the four annual oncology meetings is granted only to data of high scientific or clinical importance and is the highest-tier session category at the meeting. The chart below reports each Chinese-origin sponsor’s LBA count as a share of total accepted abstracts across all four meetings for 2022–2025.

ASCO 2026 adds three Late-Breaking Oral Abstract acceptances on Chinese-attributed assets: LBA4 in the Plenary Session (HARMONi-6: ivonescimab + chemotherapy vs tislelizumab + chemotherapy in squamous NSCLC, OS readout; Akeso and BeOne), LBA6005 as an Oral Abstract (adjuvant sintilimab + capecitabine in locoregionally advanced nasopharyngeal carcinoma; Innovent), and LBA1003 as an Oral Abstract (SystImmune iza-bren versus physician’s choice of chemotherapy in TNBC, Phase III). A fourth Late-Breaking item, LBA3515 (mRCAT-III: short-course radiotherapy + CAPOX + tislelizumab in MMR-proficient / MSS rectal cancer; BeOne), is in a Rapid Oral session. Four Chinese-attributed Late-Breaking acceptances at a single meeting represent a step-change from the 2022–2025 baseline.

Alphamab Oncology is an outlier in the LBA-share distribution: a small base (23 total abstracts in the period) and an LBA share of 4.3%. Chinese academic medical centers tracked in the dataset (Fudan University, Zhejiang University, Peking Union Medical College Hospital, and others) recorded zero Late-Breaking acceptances over the same period, consistent with the pattern that LBAs are predominantly submitted by industry sponsors rather than academic sites. The total volume of LBA submissions from Chinese-origin sponsors is small in absolute terms; an LBA acceptance at ASCO 2026 is therefore a notable event for the originating sponsor regardless of asset.

§10 Conference distribution: where each sponsor concentrates abstract output (ASCO vs ESMO vs AACR vs ASH)

Chinese-origin sponsors do not distribute abstract output evenly across the four annual meetings. The distribution pattern is informative about portfolio composition. A sponsor with an ASH-weighted distribution indicates hematology focus (zanubrutinib is the canonical example). An ASCO-weighted distribution indicates solid-tumor focus. An AACR-weighted distribution indicates preclinical and translational emphasis. An ESMO-weighted distribution typically reflects European clinical positioning, often tied to ex-China licensing arrangements with European-headquartered partners.

§11 Forward observation calendar and reporting cadence

The Post-ASCO 2026 edition ships on the day following the close of the meeting. Scope:

• 11.1 LBA4 Plenary outcome as cross-read on the HARMONi-3 squamous interim miss. Reported OS results of ivonescimab + chemotherapy vs tislelizumab + chemotherapy in squamous NSCLC (Chinese sites), read against the April 30, 2026 HARMONi-3 squamous interim PFS miss vs pembrolizumab (global). Three interpretive outcomes: comparator-strength reading (LBA4 strong OS → pembro is the tougher control; broad 1L U.S. thesis intact), geographic / population-effect reading (LBA4 weak OS → China-vs-global gap is doing the work; broad 1L thesis materially de-risked), or intermediate. Commercial-positioning consequences for Akeso, Summit Therapeutics, and BeOne assessed under each.
• 11.1a HARMONi PDUFA — November 14, 2026. Inside the report’s forward calendar window: FDA action on Summit’s BLA for ivonescimab + chemotherapy in EGFR-mutated non-squamous NSCLC after prior EGFR-TKI therapy. First U.S. approval decision for the asset, independent of HARMONi-3 and HARMONi-6.
• 11.2 SHR-A1811 Phase 3 readout (Oral Abstract 3505, Sunday morning). Reported results of trastuzumab rezetecan versus standard of care in HER2-positive advanced colorectal cancer, with assessment of the data’s implications for Hengrui’s broader trastuzumab rezetecan program and Glenmark’s ex-territory development.
• 11.3 SystImmune Late-Breaking and Oral Abstracts on izalontamab brengitecan (LBA1003 and Oral Abstract 4008). Confirmation or non-confirmation of the multi-tumor pivotal-development pattern visible in the program, with assessment of business-development implications.
• 11.4 First licensee-led ASCO presentations on Chinese-origin assets. AstraZeneca on savolitinib (Rapid Oral 4011) is the first scheduled instance in the dataset. Any Takeda-authored IBI343 or fruquintinib presentations will be flagged on first appearance.
• 11.6 Historical back-fill for promoted emerging sponsors. Kelun-Biotech, Ascentage Pharma, Hansoh Pharma, Mabwell Bioscience, Suzhou ZelGen, and MediLink Therapeutics have been added to the tracked sponsor set for this edition; historical attribution across ASCO Annual, ESMO Congress, AACR Annual, and ASH Annual will be back-filled in the post-ASCO 2026 edition. Bio-Thera Solutions and Chia Tai Tianqing are carried in the emerging-sponsor table pending asset-level mechanism confirmation before full inclusion.

Subsequent reporting cycle: ESMO Congress 2026. ESMO is the next major data window for Chinese-origin oncology assets. Anticipated items include the HARMONi-3 final PFS readout (ivonescimab + chemotherapy vs pembrolizumab + chemotherapy, global, the broader 1L NSCLC U.S.-pathway trial) expected 2H 2026 following the April 30, 2026 interim PFS miss; the November 14, 2026 PDUFA decision on ivonescimab in EGFR-mutated non-squamous NSCLC post-EGFR-TKI (the global HARMONi trial); Phase II expansion data on IBI343 from Takeda; AstraZeneca-led oncology readouts from the CSPC partnership; and any post-LBA4 follow-up on the HARMONi-6 OS readout from ASCO 2026. Volume 1 Issue 3 of AssayOne · China Watch Oncology, the first paid monthly edition, ships in late June 2026 and covers ESMO interim updates plus Phase 1 and Phase 2 trial registrations from the 2024–2025 out-licensing cohort.

§12 Twelve-month observation calendar: sponsors, tickers, and the dated events that resolve each thesis

The table below catalogues the tracked Chinese-origin sponsors against the binary events scheduled over the next twelve months that resolve the central analytical question for each. The brief does not include buy or sell recommendations, price targets, or probability-weighted scenarios; this is an event calendar, not investment research. Readers are expected to overlay their own valuation, position-sizing, and risk frameworks. Tickers are listed where the sponsor is publicly traded; private sponsors are marked accordingly. Cash position, share-price, and institutional-ownership data are deliberately omitted (sourced from standard public market data feeds).

12.1 Cash and dilution watch

For the smaller-cap and pre-revenue sponsors in the cohort, near-term financing dynamics materially affect the timeline on each thesis above. The following sponsors warrant standing cash-position monitoring (data sourced from latest 10-Q / 6-K / Hong Kong interim filings; not reproduced here):

• 3D Medicines (HKEX 1244.HK) — cross-conference abstract output collapsed from peak 69 abstracts in 2021 to 7–10 in 2023–2025. Cash position should be assessed against the franchise-erosion thesis in §7.2.
• Mabwell (STAR 688062.SH) — investment-stage; cash adequacy against the Phase III cervical 9MW2821 readout window.
• MediLink Therapeutics (private) — runway is a function of Roche partnership cadence; visible only through partnership milestone disclosures.
• SystImmune (private) — runway is a function of follow-on private financing or potential IPO timing; the multi-tumor iza-bren signal may trigger fundraising activity in late 2026.

12.2 Where the cohort signal is weak

The dataset identifies sponsors where the conference signal does not support sustained engagement at the analyst-attention level:

• 3D Medicines (1244.HK) — output collapse documented in §7.2; pre-2023 catalog requires reassessment before any forward thesis.
• The prior AZ–CSPC chronic-disease portfolio entry has been removed from the current cohort table. As of issue date, the publication carries two verified AstraZeneca–CSPC transactions: YS2302018, an Lp(a) inhibitor licensed in October 2024, and the eight-program obesity and type 2 diabetes portfolio announced January 30, 2026.

Methodology note for §12. The events listed above are scheduled or company-guided as of issue date. Conference and regulatory dates are sourced from ASCO meeting program records, ESMO Congress 2026 published schedule, FDA documents, and originator press releases. None of the events constitutes a recommendation. Where a sponsor is privately held, the binary event resolves the underlying clinical or partnership question without an equity-side translation step.